New Type 1 Diabetes Study Completes Enrollment as Researchers Test Potential Hypoglycemia Treatment

Cadisegliatin is an experimental oral medication being developed by vTv Therapeutics. It belongs to a class of drugs called glucokinase activators and is designed to work specifically in the liver. If approved, it would be taken by mouth rather than injected, which differs from insulin and many other Type 1 diabetes treatments.

The drug is intended to be used alongside insulin therapy, not instead of it. This type of add-on treatment is called adjunctive therapy.

Hypoglycemia—episodes of dangerously low blood sugar—remains a significant challenge for people with Type 1 diabetes, even with modern insulin pumps and continuous glucose monitors. Severe low blood sugar can cause seizures, loss of consciousness, and other serious complications.

Researchers hope that cadisegliatin may help reduce how often these episodes occur or how severe they are, offering people with Type 1 diabetes more protection and peace of mind during daily life.

The CATT1 study (Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes) is a Phase 3 clinical trial, which means it tests whether a drug works and is safe in a larger group of patients. A total of 166 people with Type 1 diabetes have been enrolled in the study.

Phase 3 is a late stage of drug development. If results are positive and the drug is approved by regulators, it could become available to patients. Topline results—the initial findings from this completed trial—are expected to be announced in mid-2027.

An estimated 9.5 million people worldwide currently live with Type 1 diabetes, and that number is projected to grow to 14.7 million by 2040. New treatment options that can reduce hypoglycemia risk would address an unmet medical need for many of these individuals.

The fact that cadisegliatin received Breakthrough Therapy designation from the FDA suggests that early evidence showed promise. This status can help speed the development and review process for treatments that address serious conditions and show potential benefit over existing options.

Origin: finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.